These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37779773)

  • 21. Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients.
    El-Gebaly F; Abou-Saif S; Elkadeem M; Helmy A; Abd-Elsalam S; Yousef M; Elkhouly RA; Amer IF; El-Demerdash T
    Curr Cancer Drug Targets; 2019; 19(11):896-905. PubMed ID: 31538897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The potential of soluble programmed death-ligand 1 (sPD-L1) as a diagnosis marker for colorectal cancer.
    Shao W; Xu Y; Lin S; Gao J; Gao J; Wang H
    Front Oncol; 2022; 12():988567. PubMed ID: 36052227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
    Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Expression of soluble programmed death-1, soluble programmed death ligand 1 proteins and immune status in patients with oral lichen planus].
    Luo L; Shu M; Li S; Cai Y
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2015 Oct; 50(10):585-9. PubMed ID: 26757624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy.
    Kim HJ; Park S; Kim KJ; Seong J
    Radiother Oncol; 2018 Oct; 129(1):130-135. PubMed ID: 29366520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
    Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O
    Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy.
    Tanizaki J; Kuroda H; Yokoyama T; Takahama M; Shoda H; Nakamura A; Kitamura Y; Mamesaya N; Kadota Y; Sawa K; Okishio K; Okada M; Suminaka C; Noda K; Sakai K; Chiba Y; Nishio K; Chamoto K; Honjo T; Yamamoto N; Nakagawa K; Hayashi H
    JTO Clin Res Rep; 2023 Dec; 4(12):100590. PubMed ID: 38029041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma.
    Lu T; Chen Y; Li J; Guo Q; Lin W; Zheng Y; Su Y; Zong J; Lin S; Ye Y; Pan J
    Onco Targets Ther; 2020; 13():1757-1765. PubMed ID: 32161471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization.
    Ma XL; Qu XD; Yang WJ; Wang BL; Shen MN; Zhou Y; Zhang CY; Sun YF; Chen JW; Hu B; Gong ZJ; Zhang X; Pan BS; Zhou J; Fan J; Yang XR; Guo W
    Clin Chim Acta; 2020 Dec; 511():67-74. PubMed ID: 32979338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Pai SI; Cohen EEW; Lin D; Fountzilas G; Kim ES; Mehlhorn H; Baste N; Clayburgh D; Lipworth L; Resteghini C; Shara N; Fujii T; Zhang J; Stokes M; Wang H; Twumasi-Ankrah P; Wildsmith S; Khaliq A; Melillo G; Shire N
    J Transl Med; 2019 Dec; 17(1):429. PubMed ID: 31878938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Soluble programmed death-1 and soluble programmed death ligand 1 protein expression and immune status in patients with recurrent aphthous ulcer].
    Nan J; Liang L; Li L; Xiaoqin S; Xing J; Yang C
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2017 Jun; 35(3):286-290. PubMed ID: 28675014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PREDICTIVE VALUE OF SOLUBLE PROGRAMMED CELL DEATH LIGAND-1 IN THE PROGRESSION OF SEPTIC PATIENTS TO CHRONIC CRITICAL ILLNESS IN THE INTENSIVE CARE UNIT: A PROSPECTIVE OBSERVATIONAL CLINICAL STUDY.
    Zeng C; Li X; Lu Z; Mu G; Deng Y
    Shock; 2023 Aug; 60(2):163-171. PubMed ID: 37267247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
    Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
    Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis.
    Scirocchi F; Strigari L; Di Filippo A; Napoletano C; Pace A; Rahimi H; Botticelli A; Rughetti A; Nuti M; Zizzari IG
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer.
    He Y; Zhang X; Zhu M; He W; Hua H; Ye F; Zhou X; Chen N; Li Y; Zhong W; Wu G; Cai H; Jiang W
    J Transl Med; 2023 Jan; 21(1):25. PubMed ID: 36639643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis.
    Shen H; Ji Y; Zhou D; Zhang Y; Wang W; Sun J; Zhang W
    Hematology; 2019 Dec; 24(1):392-398. PubMed ID: 30890046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
    Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
    [No Abstract]   [Full Text] [Related]  

  • 38. Serum sPD-1 and sPD-L1 as Biomarkers for Evaluating the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients.
    Li Y; Cui X; Yang YJ; Chen QQ; Zhong L; Zhang T; Cai RL; Miao JY; Yu SC; Zhang F
    Clin Breast Cancer; 2019 Oct; 19(5):326-332.e1. PubMed ID: 31176611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
    Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
    Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Significance of Serum PD-L1 Level in Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Combination Cytotoxic Chemotherapy.
    Fu R; Jing CQ; Li XR; Tan ZF; Li HJ
    Cancer Manag Res; 2021; 13():4935-4946. PubMed ID: 34188546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.